Opaleye Management Inc.
About Opaleye Management Inc.’s 13F portfolio
Opaleye Management Inc. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Opaleye Management Inc. reported $1.1B across 58 US-listed positions (). Its largest position is LIQUIDIA CORPORATION (LQDA) at 18% of the reported book, and its ten biggest holdings make up 65% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: LQDA LIQUIDIA CORPORATION | — — | 18% | 2.4M | $195.1M |
| 2 | NASDAQ: ETON ETON PHARMACEUTICALS INC | — — | 9.4% | 2.9M | $103.5M |
| 3 | NASDAQ: HROW HARROW INC | — — | 9.2% | 2.4M | $101.9M |
| 4 | NASDAQ: IRON DISC MEDICINE INC | — — | 5.7% | 855K | $62.5M |
| 5 | NASDAQ: URGN UROGEN PHARMA LTD | — — | 4.8% | 1.4M | $53.0M |
| 6 | NASDAQ: APGE APOGEE THERAPEUTICS INC | — — | 4.7% | 390K | $51.8M |
| 7 | NASDAQ: MGTX MEIRAGTX HLDGS PLC | — — | 4.3% | 3.5M | $48.0M |
| 8 | NASDAQ: SLGL SOL-GEL TECHNOLOGIES LTD | — — | 3.4% | 500K | $37.1M |
| 9 | NASDAQ: RZLT REZOLUTE INC | — — | 3.0% | 6.3M | $32.8M |
| 10 | NASDAQ: TGTX TG THERAPEUTICS INC | — — | 2.7% | 535K | $29.4M |
| 11 | NASDAQ: IMMX IMMIX BIOPHARMA INC | — — | 2.2% | 2.3M | $24.2M |
| 12 | NASDAQ: CBIO CRESCENT BIOPHARMA INC. | — — | 2.2% | 1.3M | $23.7M |
| 13 | NASDAQ: STOK STOKE THERAPEUTICS INC | — — | 2.1% | 700K | $22.9M |
| 14 | NASDAQ: ACOG ALPHA COGNITION INC | — — | 1.9% | 2.9M | $20.9M |
| 15 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | — — | 1.8% | 500K | $20.3M |
| 16 | NASDAQ: RVMD REVOLUTION MEDICINES INC | — — | 1.7% | 100K | $18.7M |
| 17 | NASDAQ: GLUE MONTE ROSA THERAPEUTICS INC | — — | 1.6% | 745K | $18.0M |
| 18 | NASDAQ: ALMS ALUMIS INC | — — | 1.4% | 550K | $15.5M |
| 19 | NASDAQ: CDXS CODEXIS INC | — — | 1.4% | 6.8M | $15.3M |
| 20 | NASDAQ: REPL REPLIMUNE GROUP INC | — — | 1.4% | 1.4M | $15.3M |
| 21 | NASDAQ: XOMA XOMA ROYALTY CORPORATION | — — | 1.3% | 338K | $14.4M |
| 22 | NASDAQ: MBX MBX BIOSCIENCES INC | — — | 1.3% | 260K | $14.4M |
| 23 | NASDAQ: RYTM RHYTHM PHARMACEUTICALS INC | — — | 1.2% | 123K | $13.6M |
| 24 | NASDAQ: EDIT EDITAS MEDICINE INC | — — | 1.1% | 3.9M | $12.5M |
| 25 | NASDAQ: PTGX PROTAGONIST THERAPEUTICS INC | — — | 1.1% | 100K | $12.3M |
Showing 1–25 of 58 positions on this page reported in this 13F.
- Healthcare99%
- AddedIRONDISC MEDICINE INC+103%$62.5M
- AddedURGNUROGEN PHARMA LTD+0.7%$53.0M
- AddedMGTXMEIRAGTX HLDGS PLC+67.2%$48.0M
- NewIMMXIMMIX BIOPHARMA INC—$24.2M
- AddedCBIOCRESCENT BIOPHARMA INC.+0.5%$23.7M
- AddedACOGALPHA COGNITION INC+13.0%$20.9M
- NewGLUEMONTE ROSA THERAPEUTICS INC—$18.0M
- NewREPLREPLIMUNE GROUP INC—$15.3M
- AddedXOMAXOMA ROYALTY CORPORATION+12.8%$14.4M
- AddedEDITEDITAS MEDICINE INC+100%$12.5M
- ReducedLQDALIQUIDIA CORPORATION−3.8%$195.1M
- ReducedHROWHARROW INC−15.3%$101.9M
- ReducedRYTMRHYTHM PHARMACEUTICALS INC−0.4%$13.6M
- ReducedQTTBQ32 BIO INC−25.9%$11.9M
- ReducedANNXANNEXON INC−26.5%$9.8M
- ReducedTRVITREVI THERAPEUTICS INC−10.2%$5.8M
- ReducedBDSXBIODESIX INC−24.4%$4.1M
- ReducedJBIOJADE BIOSCIENCES INC−66.1%$3.2M
- ReducedSNWVSANUWAVE HEALTH INC−68.8%$3.1M
- ReducedFBIOFORTRESS BIOTECH INC−14.6%$2.7M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | SLGL Sol-Gel Technologies Ltd | 13G | 16.5% · 2 classes | 540K | Filed 06 NOV 2026 |
| 2 | ACOG Alpha Cognition Inc. | 13G | 14.2% · 2 classes | 3.1M | Filed 24 JUL 2026 |
| 3 | QTTB Q32 Bio Inc. | 13G | 8.7% | 1.3M | Filed 20 FEB 2026 |
| 4 | ETON ETON PHARMACEUTICALS, INC. | 13G | 8.5% | 2.4M | Filed 06 NOV 2026 |
| 5 | GOSS Gossamer Bio, Inc. | 13G | 7.0% · 2 classes | 427K | Filed 06 NOV 2026 |
Showing all 5 disclosed stakes.
Reading Opaleye Management Inc.’s 13F portfolio
Opaleye Management Inc.’s $1.1B 13F book is spread across 58 reported positions and is highly concentrated — its ten largest positions alone are 65% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are LQDA, ETON, HROW, IRON and URGN, led by LIQUIDIA CORPORATION (LQDA) at 18% of the portfolio. The heaviest sector exposure is Healthcare (99%).
What Opaleye Management Inc. changed last quarter
Between 2026-03-31 and Q2 2026, Opaleye Management Inc. was a net buyer: it opened 13 new positions and added to 15 more, while trimming 13 and closing 9 outright. Against a 58-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was DISC MEDICINE INC (IRON), and its biggest reduction was LIQUIDIA CORPORATION (LQDA).
What a 13F does and doesn’t reveal
A 13F captures only Opaleye Management Inc.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Opaleye Management Inc. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Opaleye Management Inc.'s profile on this page is built directly from those filings.
How current is the 13F data on Opaleye Management Inc.'s page?
It reflects Opaleye Management Inc.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Opaleye Management Inc. files its next quarterly report, this page refreshes automatically.
Can I see Opaleye Management Inc.'s complete list of holdings?
This page highlights Opaleye Management Inc.'s largest positions rather than all 58 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Opaleye Management Inc.'s filings.
Does a 13F show everything Opaleye Management Inc. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Opaleye Management Inc.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Opaleye Management Inc. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

